SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is trending due to heightened speculation around impending Phase 3 results for its lead AML immunotherapy, GPS, with the CEO's recent remarks on "curative outcomes" fueling strong community belief in a positive data readout and potential buyout. This has intensified discussions of a significant short squeeze as institutional accumulation is noted and the stock approaches new highs.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is trending after closing a $40 million private placement, which has ignited a rapid surge in its share price. The community is actively debating the implications of the placement's per-share cost versus current trading levels, with many traders anticipating further momentum and a potential short squeeze.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is surging amid escalating tensions in the Middle East and the effective closure of the Strait of Hormuz, driving community debate on whether oil's parabolic rise is sustainable against potential strategic reserve releases by the G7.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following strong 12-month Phase 2 data for its bladder cancer candidate NDV-01 and significant new financing to advance its clinical pipeline. The community is actively discussing the promising trial results and the implications of the capital raise, with some monitoring for potential dilution.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

Calamp Corp. is currently trending due to its Chapter 11 bankruptcy filing and plan to go private, which is expected to eliminate existing shareholder equity. Investors are actively discussing the impending delisting and the ultimate value of their holdings.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

AGH is trending due to its announced merger with drone manufacturer Powerus, a company backed by Eric Trump and Donald Trump Jr., which is transforming it from a golf course operator into a public defense-drone entity. This significant pivot is driving massive community discussion and high volume, fueled by anticipation of government contracts amid increasing demand for U.S.-made drone technology.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. trends amid the upcoming CEO transition to Josh D'Amaro on March 18 and the successful debut of Pixar's 'Hoppers,' fueling community discussion over whether these catalysts, alongside a new stock buyback, can address ongoing concerns about content performance and valuation.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is surging on heightened speculation surrounding a potential acquisition, particularly an eBay deal, alongside community excitement following recent social media activity from "Roaring Kitty" and anticipation for its upcoming Q4 earnings report, fueling widespread chatter about a significant breakout.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is surging as its new agreement with Novo Nordisk to sell branded Ozempic and Wegovy, coupled with the dismissal of a patent lawsuit, fundamentally transforms its market position in the booming GLP-1 sector. The community is actively debating a massive short squeeze and long-term upside, with many seeing the move as eliminating the main bear thesis and validating Hims' growth strategy.

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Solid Biosciences is trending following an oversubscribed $240 million private placement bolstering its cash runway and recent positive regulatory updates across its Duchenne, Friedreich's Ataxia, and cardiac gene therapy programs, igniting strong institutional interest and short-squeeze speculation among the community.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Positive Outlook for TCRX Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright...

FY2030 Earnings Estimate for TCRX Issued By HC Wainwright

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of TScan Therapeutics in a note issued to investors on...

TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00

Wedbush lifted their price target on TScan Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a research note on Thursday...

TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate...

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +34.31% and -37.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Breakdown: TScan Therapeutics Q4

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Wednesday

TScan Therapeutics (NASDAQ:TCRX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...

TScan Therapeutics (NASDAQ:TCRX) Trading Up 4.6% - Here's What Happened

TScan Therapeutics (NASDAQ:TCRX) Shares Up 4.6% - Here's Why...

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has received an average rating of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Current Price	$1.23
Prev Close	$1.12
Open	$1.10
Dividend Yield	0.00%
50-Day Moving Average	$1.06
Beta	1.22
Avg. Volume	461,574.98
PE Ratio	-1.12

52-Week High	$2.57
52-Week Low	$0.8824
Market Capitalization	$63.56M
EPS (Annual)	-$0.9999
Price to Book	0.52
Revenue Per Employee	$72,711.27

TCRX
Tscan Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCRX News

TCRXTscan Therapeutics Inc